Get the Stockscreener App
562.97
0.03%
-0.155
After Hours:
563.72
0.755
+0.13%
Idexx Laboratories Inc stock is traded at $562.97, with a volume of 734.26K.
It is down -0.03% in the last 24 hours and down -1.16% over the past month.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
See More
Previous Close:
$563.12
Open:
$569.21
24h Volume:
734.26K
Relative Volume:
1.35
Market Cap:
$44.71B
Revenue:
$4.30B
Net Income/Loss:
$1.06B
P/E Ratio:
43.04
EPS:
13.0798
Net Cash Flow:
$1.04B
1W Performance:
-0.94%
1M Performance:
-1.16%
6M Performance:
-21.83%
1Y Performance:
+18.50%
1-Day Range:
$550.00
$584.72
1-Week Range:
$544.01
$584.72
52-Week Range:
$465.00
$769.98
Idexx Laboratories Inc Stock (IDXX) Company Profile
Name
Idexx Laboratories Inc
Sector
Industry
Phone
(207) 556-0300
Address
ONE IDEXX DRIVE, WESTBROOK, ME
Compare IDXX vs TMO, DHR, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IDXX
Idexx Laboratories Inc
|
562.97 | 44.73B | 4.30B | 1.06B | 1.04B | 13.08 |
TMO
Thermo Fisher Scientific Inc
|
466.76 | 171.91B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
174.63 | 123.18B | 24.78B | 3.68B | 5.29B | 5.1743 |
WAT
Waters Corp
|
342.75 | 29.63B | 3.17B | 642.63M | 516.49M | 10.77 |
A
Agilent Technologies Inc
|
117.53 | 31.70B | 7.07B | 1.29B | 993.00M | 4.5355 |
Idexx Laboratories Inc Stock (IDXX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | Citigroup | Neutral |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Oct-31-25 | Upgrade | Stifel | Hold → Buy |
| Oct-01-25 | Initiated | UBS | Neutral |
| Aug-05-25 | Reiterated | BTIG Research | Buy |
| Jul-01-25 | Initiated | Jefferies | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Outperform |
| Jul-25-24 | Initiated | BTIG Research | Buy |
| Jan-30-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-07-23 | Initiated | Exane BNP Paribas | Outperform |
| Dec-04-23 | Upgrade | Cleveland Research | Neutral → Buy |
| Aug-02-23 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Jul-25-22 | Downgrade | Stifel | Buy → Hold |
| Jul-21-22 | Upgrade | Goldman | Neutral → Buy |
| Jul-12-22 | Initiated | Piper Sandler | Overweight |
| May-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-08-22 | Initiated | Atlantic Equities | Overweight |
| Nov-18-21 | Initiated | Morgan Stanley | Overweight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-12-21 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-17-21 | Initiated | Barclays | Overweight |
| Sep-09-19 | Initiated | Goldman | Neutral |
| May-23-19 | Initiated | Guggenheim | Buy |
| Nov-02-18 | Reiterated | BofA/Merrill | Buy |
| May-07-18 | Reiterated | Stifel | Buy |
| Jan-16-18 | Initiated | Piper Jaffray | Overweight |
| Aug-23-17 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-28-17 | Upgrade | CL King | Neutral → Buy |
| Feb-03-17 | Downgrade | Feltl & Co. | Hold → Sell |
| Sep-29-16 | Resumed | BofA/Merrill | Neutral |
| Aug-16-16 | Reiterated | Stifel | Buy |
| Aug-03-16 | Upgrade | Northcoast | Sell → Neutral |
| Jul-20-16 | Reiterated | Canaccord Genuity | Buy |
| Apr-19-16 | Reiterated | Canaccord Genuity | Buy |
| Apr-01-16 | Initiated | CL King | Neutral |
| Mar-21-16 | Reiterated | Stifel | Buy |
| Feb-04-16 | Initiated | Credit Suisse | Outperform |
| Oct-29-15 | Reiterated | Stifel | Buy |
| Aug-28-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Aug-13-15 | Reiterated | Stifel | Buy |
| Jul-23-15 | Reiterated | Canaccord Genuity | Buy |
View All
Idexx Laboratories Inc Stock (IDXX) Latest News
BofA cuts Idexx Laboratories stock price target on macro concerns By Investing.com - Investing.com South Africa
IDEXX (NASDAQ: IDXX) lifts Q1 profit and ramps up buybacks - Stock Titan
BofA cuts Idexx Laboratories stock price target on macro concerns - Investing.com
IDEXX Laboratories Q1 Earnings Call Highlights - Yahoo Finance
IDEXX Laboratories, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:IDXX) 2026-05-05 - Seeking Alpha
IDEXX Laboratories, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
IDEXX Q1 2026 slides: raised guidance on strong diagnostic growth - Investing.com
IDEXX Stock Up on Q1 Earnings & Revenue Beat, Margins Rise, '26 View Up - Yahoo Finance
Idexx Laboratories Raises Guidance On Higher Clinical Visits, Diagnostic Frequency - Benzinga
Transcript: IDEXX Laboratories Q1 2026 Earnings Conference Call - Benzinga
IDEXX beats expectations on Q1 results, raises 2026 outlook - Mainebiz
IDEXX Laboratories Releases Q1 2026 Financial Results - AlphaStreet
IDEXX Laboratories Q1 Comparable Earnings, Revenue Rise - marketscreener.com
MSN Money - MSN
Idexx Laboratories (IDXX) Q1 Earnings and Revenues Surpass Estimates - Yahoo Finance
IDEXX Laboratories (NASDAQ:IDXX) Beats and Raises on Strong Demand, Sending Shares Up - ChartMill
Earnings Flash (IDXX) IDEXX Laboratories Posts Q1 Comparable EPS $3.30, vs. FactSet Est of $3.39 - marketscreener.com
IDEXX LABS ($IDXX) Releases Q1 2026 Earnings - Quiver Quantitative
Earnings Flash (IDXX) IDEXX Laboratories, Inc. Reports Q1 Revenue $1.14B, vs. FactSet Est of $1.12B - marketscreener.com
IDEXX Laboratories : Earnings snapshot Q1 2026 - marketscreener.com
Idexx: Q1 Earnings Snapshot - KVUE
IDEXX posts Q1 revenue $1.141B, EPS $3.47; raises 2026 revenue and EPS outlook - TradingView
Press Release: IDEXX Laboratories Announces First Quarter Results - Moomoo
Long-Term Leaders: Boston Scientific Joins Watchlist, Motorola Out - Investor's Business Daily
IDEXX (NASDAQ: IDXX) director defers $24,375 into stock units - Stock Titan
IDEXX Laboratories Q1 2026 earnings preview - MSN
IDEXX earnings up next as softer vet visits cloud Q1 expectations By Investing.com - Investing.com South Africa
IDEXX earnings up next as softer vet visits cloud Q1 expectations - Investing.com Nigeria
What you need to know ahead of IDEXX Laboratories' earnings release - MSN
IDEXX Laboratories, Inc. $IDXX Stock Position Lifted by Danske Bank A S - MarketBeat
IDEXX Laboratories Inc | SCHEDULE 13G: Others - Moomoo
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day - MarketWatch
Here's How IDEXX Laboratories Is Placed Ahead of Q1 Earnings - Yahoo Finance
Oppenheimer Asset Management Inc. Raises Position in IDEXX Laboratories, Inc. $IDXX - MarketBeat
Vanguard Capital Management (IDXX) reports 5.98M shares, 7.51% stake - Stock Titan
IDEXX Laboratories, Inc. $IDXX Stake Boosted by Wealthfront Advisers LLC - MarketBeat
IDEXX Laboratories Stock (US45168D1046): Set to Report Q1 2026 Earnings - AD HOC NEWS
UBS Group AG Has $192.78 Million Holdings in IDEXX Laboratories, Inc. $IDXX - MarketBeat
Neuberger Mid Cap Growth Fund's IDEXX Laboratories Inc(IDXX) Holding History - GuruFocus
IDEXX Laboratories Experiences Valuation Adjustment Amid Strong Financial Indicators - Markets Mojo
IDEXX Laboratories Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
How Idexx Laboratories Inc. (IDXX) Affects Rotational Strategy Timing - Stock Traders Daily
Transamerica Mid Cap Growth's IDEXX Laboratories Inc(IDXX) Holding History - GuruFocus
Mitsubishi UFJ Trust & Banking Corp Raises Stake in IDEXX Laboratories, Inc. $IDXX - MarketBeat
Sanctuary Advisors LLC Purchases 7,186 Shares of IDEXX Laboratories, Inc. $IDXX - MarketBeat
Comerica Bank Sells 9,639 Shares of IDEXX Laboratories, Inc. $IDXX - MarketBeat
FUNDSMITH INVESTMENT SERVICES LTD.'s IDEXX Laboratories Inc(IDXX) Holding History - GuruFocus
IDEXX Laboratories (IDXX) Q4 2024 earnings summary - Quartr
IDEXX Laboratories Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
UBS Maintains IDEXX Laboratories Inc(IDXX.US) With Hold Rating, Cuts Target Price to $640 - 富途牛牛
IDEXX Laboratories (IDXX) Projected to Post Earnings on Tuesday - MarketBeat
Idexx Laboratories Inc Stock (IDXX) Financials Data
Revenue
Net Income
Cash Flow
EPS
13.54%
2.26%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):